ALISO VIEJO, CA — Ophthalmic medical device firm RxSight Inc. has raised $132 million in an initial public offering.
The company sold more than 8.2 million shares of common stock in the IPO. It now trades on the Nasdaq Global Market under the ticker symbol “RXST.”
RxSight is a commercial-stage company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system “is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery,” according to the firm.
More from the press release:
RxSight, Inc., an ophthalmic medical device company, today announced the closing of its initial public offering of 7,350,000 shares of common stock on August 3, 2021, as well as the partial exercise of the underwriters’ option to purchase an additional 898,594 additional shares of common stock, which closed on August 4, 2021, in each case at the initial public offering price of $16.00 per share. With the addition of the partial exercise of the underwriter’s option to purchase additional shares, the total number of shares sold by RxSight in the offering increased to 8,248,594 shares of common stock, and the aggregate gross proceeds to RxSight before deducting underwriting discounts and commissions and offering expenses, were approximately $132 million. Shares of RxSight’s common stock began trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.”
J.P. Morgan Securities LLC and BofA Securities, Inc. acted as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC also acted as a book-running manager of the offering. Wells Fargo Securities, LLC acted as lead manager for the offering. BTIG, LLC acted as co-manager for the offering.
A registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained by contacting:
J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;
BofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or
SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.
Advertisement
